INDIANAPOLIS, Oct. 23, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy. “We are very pleased that the FDA has […]
Great Place to Work® recognizes Novartis for outstanding workplace culture Inclusion in list of best employers based on survey of 7,200 companies around the world Novartis ranked high for the pride associates take in their work, their teams and the organization Basel, October 22, 2013 – Novartis is pleased to announce that it has been […]
DUBLIN, Ohio, Oct. 15, 2013 — The Cardinal Health Surgical Clipper, which promotes perioperative safety combined with speed and simplicity, is now available. “Technology-enabled, evidence-based medicine can help improve quality, ensure safety and increase efficiencies,” said Shaden Marzouk, MD, vice president of Clinical Affairs at Cardinal Health, “and the Cardinal Health Surgical Clipper enables effective […]
California, USA, October 15, 2013 – Sandoz welcomes California Governor Jerry Brown’s veto of legislation that threatened to restrict patient access to biosimilars – high-quality follow-on versions of existing biologic medicines to treat complex disorders including cancer and autoimmune diseases. Mark McCamish, global head of Sandoz Biopharmaceutical Development, who wrote a personal letter to the governor […]
Accuray Incorporated- One company with two great technologies who develops personalized, leading-edge treatment solutions that help cancer patients live longer, better lives. SOURCE: Accuray
Omalizumab significantly reduced itch and hives caused by chronic spontaneous urticaria (CSU) as early as Week 1; benefit sustained over 24 weeks of active treatment[1] Omalizumab 300 mg was nearly twice as effective in improving patients’ quality of life within 12 weeks of treatment versus placebo[1] ASTERIA I is the final omalizumab CSU registration study […]
New four-year data showed that continued Gilenya treatment reduced brain volume loss by one third when compared to delaying Gilenya by two years. MS patients with higher rates of brain volume loss were more likely to experience disease progression. Patients who remained free of disease had consistently lower rates of brain volume loss compared to […]
Data Supports Growing Use of CyberKnife® SBRT for Prostate Cancer SUNNYVALE, Calif., October 3, 2013 and ASTRO 2013 (Atlanta)– Accuray Incorporated (Nasdaq: ARAY) announced today that studies presented at the 55th Annual American Society for Radiation Oncology (ASTRO) Meeting in Atlanta, September 22 – 25, 2013 continue to reinforce evidence of clinical and quality of life benefits for […]
Secukinumab (AIN457) patients’ skin cleared faster and for longer than Enbrel® (etanercept) patients, beginning as early as Week 2[1] Study also showed twice as many secukinumab patients experienced clear or almost clear skin by Week 12 versus Enbrel[1] Head-to-head study of secukinumab and Enbrel part of largest clinical program completed in moderate-to-severe plaque psoriasis with […]
Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual’s level of disability Recovering from a relapse can take weeks […]